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Abstract
The overall vaccine effectiveness of the monovalent rotavirus vaccine in an observational, prospective, multicentre, hospital-based case–
control study in Belgium (RotaBel) was 90%. However, rotavirus genotype and co-infecting pathogens are important parameters to take into
account when assessing vaccine effectiveness. In this study we specifically investigated the effect of rotavirus genotypes and co-infecting
pathogens on vaccine effectiveness of the monovalent vaccine. In addition, we also investigated the effect of co-infecting pathogens on
disease severity. From February 2008 to June 2010 stool samples of rotavirus gastroenteritis cases of a random sample of 39 Belgian
hospitals were collected and subsequently genotyped. Fisher’s exact tests were performed to investigate the relationships between
rotavirus genotype, co-infecting pathogens and disease severity. The vaccine effectiveness of a full series of the monovalent rotavirus vaccine
against hospitalized rotavirus gastroenteritis caused by G1P[8] rotavirus strains was 95% (95% CI 77.5–98.7). Against G2P[4], the vaccine
effectiveness was 85% (95% CI: 63.7–93.8). G4P[8]- and G3P[8]-specific vaccine effectiveness was 90% (95% CI 19.2–98.7) and 87% (95% CI
5.2 to 98.4), respectively. A post-hoc analysis showed that the genotype distribution was significantly related to the vaccination status
(p <0.001), whereby G2P[4] strains were proportionally more prevalent in vaccinated cases than in unvaccinated cases. No statistical
associations were found between co-infection status and vaccination status, Vesikari severity score or rotavirus genotype. The high vaccine
effectiveness against the individual genotypes implies robust protection of the monovalent rotavirus vaccine against hospitalized rotavirus
gastroenteritis caused by the major human rotavirus genotypes. The prevalence of G2P[4] requires continued monitoring.
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Introduction
Globally, rotavirus is the most common cause of severe acute
gastroenteritis in infants and young children [1]. The two outer
capsid proteins, VP4 and VP7, are used in a dual classification
system, where VP4 determines the P-type and VP7 determines
the G-type. Although 27 G-types and 37 P-types are currently
known, only a few G- and P-genotype combinations (G1P[8],
G2P[4], G3P[8], G4P[8], G9P[8] and G12P[8]) substantially
contribute to the burden of disease in humans [2,3].
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Comparison studies using RNA–RNA hybridization assays
or complete genome sequencing of all 11 rotavirus gene
segments have revealed the existence of two major genotype
constellations, represented by reference strains Wa and DS-1
[4,5]. The majority of human P[8] rotaviruses possess a
Wa-like genotype constellation sharing highly similar gene
segments for the majority of their genome (except for the VP7
gene segment) and are (partially) homotypic to the RotarixTM
G1P[8] vaccine strain. The DS-1-like genotype constellation,
containing human G2P[4] rotaviruses, are distantly related to
the Wa-like rotaviruses with the majority of their gene
segments sharing <85% nucleotide identity and are therefore
fully heterotypic to the RotarixTM G1P[8] vaccine strain [4].
Many epidemiological studies conducted worldwide have
revealed strong temporal and geographical genotype fluctua-
tions [6]. Currently, the factors causing these fluctuations are
largely unknown, although immunity present in a population
due to previous virus exposure, and unknown stochastic
variables are likely to play an important role [7].
Recently, two live-attenuated oral rotavirus vaccines, a
monovalent human rotavirus vaccine (RotarixTM; Glaxo-
SmithKline Vaccine, Rixensart, Belgium) and a pentavalent
human–bovine reassortant rotavirus vaccine (RotaTeqTM;
Merck & Co, Whitehouse Station, NJ, USA), have been
licensed in many countries worldwide. The monovalent
vaccine is based on the attenuated human Wa-like G1P[8]
rotavirus strain 89-12 isolated in Cincinnati, Ohio, USA in
1988 [8]. The pentavalent vaccine contains five human–bovine
reassortant rotavirus strains containing the human compo-
nents G1–G4, and P1A[8] [9]. Both vaccines were shown to
be highly effective against severe rotavirus gastroenteritis in
large clinical trials in developed countries [10–14]. The vaccine
efficacy was somewhat lower and more variable in developing
countries where phase III clinical trials have been recently
conducted for the monovalent (South Africa and Malawi) and
pentavalent (Ghana, Mali, Kenya, Bangladesh, and Vietnam)
vaccines. In these settings, the vaccine efficacy ranged from
17.6% to 81.5% [15,16]. The WHO recommended inclusion of
rotavirus vaccination in national immunization programmes
worldwide [17]. Belgian authorities made a recommendation
for rotavirus vaccination in October 2006 and partial reim-
bursement (with a co-payment by parents of €10 per dose)
has been installed since November 2006, making Belgium the
first EU country to introduce rotavirus vaccines into the
routine infant immunization schedule [18]. Based on vaccine
sales figures, a vaccine coverage of about 90% (80–85%
monovalent vaccine) was quickly reached at the start of the
2007–2008 rotavirus season and maintained in Belgian infants
[18–20]. Impressive declines in the rotavirus disease burden
were observed after rotavirus vaccine implementation in
Belgium [18,19], and several other countries, including Aus-
tralia [21], Austria [22], Brazil [23], Mexico [24], Nicaragua
[25] and the USA [26].
Previously, we have determined the overall vaccine effec-
tiveness of the monovalent vaccine in Belgium [27]. In this
paper we describe the genotype-specific vaccine effectiveness
from the above-mentioned study, together with the rotavirus
genotype distribution per vaccination status, and associations
between enteric virus co-infections and vaccination status, and
enteric virus co-infections and severity of disease. In addition,
we also compared the G1P[8] and G2P[4] genotyping results
in vaccinated and unvaccinated children in other clinical studies
to confirm our findings.
Methods
Study design
Detailed methods on the study design of RotaBel have been
described previously [27]. In summary, RotaBel is an obser-
vational, prospective, hospital-based, multicentric, matched (by
hospital and age) case–control study, designed based on the
WHO generic protocol for monitoring the impact of rotavirus
vaccination on gastroenteritis disease burden. Controls were
non-gastroenteritis patients attending an outpatient clinic at
the same hospital in the same time period as the case. For the
RotaBel study 215 gastroenteritis cases and 276 controls were
enrolled in the ‘ATP-confirmed cohort’ from February 2008 to
June 2010 [27]. ATP-confirmed cases are defined as PCR-con-
firmed hospitalized rotavirus gastroenteritis cases with at least
one matching control. Except for determining the geno-
type-specific vaccine efficacy, all analyses in this study were
conducted using the ATP-confirmed cohort (215 cases), which
was supplemented with cases that were partially vaccinated
with the monovalent vaccine, were vaccinated with the
pentavalent vaccine or had an unknown vaccination status
(33 cases), resulting in a total number of 248 cases.
To determine the genotype-specific vaccine efficacy we
included only case–control pairs that contained either a fully
vaccinated or unvaccinated case and at least one fully
vaccinated or unvaccinated control. This resulted in 160
case–controls pairs. Sequencing methods were used to
determine the rotavirus genotype from hospitalized rotavirus
gastroenteritis cases [27]. Co-infections with astrovirus,
adenovirus and norovirus were investigated using PCR-based
methods as explained below.
Virus detection and genotyping
Viral RNA (rotavirus, norovirus and astrovirus) or viral DNA
(adenovirus) was extracted using the QIAamp Viral RNA mini
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kit or the QIAamp DNA Blood Mini Kit (Qiagen/Westburg,
Leusden, the Netherlands) respectively, according to the
manufacturer’s instructions. Extracted dsRNA was denatured
at 95°C for 2 min before rotavirus RT-PCR. The RT-PCR
was carried out using the Qiagen OneStep RT-PCR Kit
(Qiagen/Westburg). Primer pairs and RT-PCR conditions
used for the different RT-PCR are shown in the Supporting
information (Table S1). The PCR amplicons were purified
with the MSB Spin PCRapace kit (Invitek, Berlin, Germany),
and sequenced using the dideoxynucleotide chain termination
method with the ABI PRISM BigDye Terminator Cycle
Sequencing Reaction kit (Perkin-Elmer Applied Biosystems,
Waltham, MA, USA) on an automated sequencer (ABI
PRISMTM 3130). The forward primers described in Table S1
were used as sequencing primers. The chromatogram
sequencing files were inspected using CHROMAS 2.3 (Techn-
elysium, Brisbane, Australia). The samples were genotyped
using BLAST analyses.
Data analysis
The vaccine effectiveness against hospitalized rotavirus gas-
troenteritis by individual genotypes and their associated 95%
CI were determined as described previously [27]. Severity of
rotavirus gastroenteritis was determined using the Vesikari
severity scale (calculated using only data available up to the
visit and not for the full duration of the episode of gastroen-
teritis) [28]. Overall associations (between rotavirus genotype
distribution, distribution of co-infecting pathogens, vaccination
status of hospitalized rotavirus gastroenteritis cases and
Vesikari scale) were investigated by Fisher’s exact test. We
also conducted an ad hoc analysis to compare genotype
distribution between vaccinated and unvaccinated cases. When
an overall significance was detected, pairwise comparisons
were conducted using a Bonferroni-corrected Fisher’s exact
test to identify the source of the observed overall differences.
Statistical analyses were performed using SAS 9.2 and SPSS
17.0 statistical software packages. The same statistical analyses
were performed on the data available from other published
clinical trials of the monovalent vaccine.
Results
Rotavirus genotype distribution
Among the 248 hospitalized rotavirus gastroenteritis cases,
G2P[4] was the most prevalent genotype (n = 125, 50.4%),
followed by G1P[8] (n = 59, 23.8%), G4P[8] (n = 23, 9.3%),
G3P[8] (n = 19, 7.7%) and G9P[8] (n = 16, 6.5%). Other
genotypes (G8P[4], G6P[14], G12P[6] and G12P[8]) were
only found once (0.4%). In two cases (0.8%) more than one
rotavirus strain was detected (Fig. 1). As shown in the
Supporting information (Fig. S1), there were only minor
changes in the genotype distribution between the three
rotavirus seasons (partially) overlapping with the study
period.
Vaccine effectiveness against hospitalized rotavirus
gastroenteritis cases by individual genotypes
The vaccine effectiveness against hospitalized rotavirus gas-
troenteritis caused by homotypic G1P[8] rotaviruses in
MIP[8]
MIMI
G12P[8]
G12P[6]
G8P[4]
G6P[14]
G9P[8]
G4P[8]
G3P[8]
G2P[4]
G1P[8]
n = 59 (23.8%)
n = 19 (7.7%)
n = 125 (50.4%)
n = 23 (9.3%)
n = 16 (6.5%)
n = 1 (0.4%){N = 248
FIG. 1. Distribution of rotavirus genotypes for 248 hospitalized rotavirus gastroenteritis cases. N = number of confirmed rotavirus cases, % = n/
number of confirmed rotavirus cases with available results 9 100. MI = mixed infection for G- and/or P-genotype.
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children receiving a full series of vaccination with the
monovalent vaccine compared with unvaccinated children,
was 95% (95% CI 78–99%). Against hospitalized rotavirus,
gastroenteritis caused by fully heterotypic G2P[4] rotavirus
strains, the vaccine effectiveness was 85% (64–94%). G4P
[8]-specific vaccine effectiveness was 90% (19–99%) and G3P
[8]-specific vaccine effectiveness was 87% (5% to 98%;
Table 1). The vaccine effectiveness against other genotypes
could not be determined because of their very low prevalence
during the study period.
Rotavirus genotype distribution per vaccination status. The geno-
type distribution of hospitalized rotavirus gastroenteritis cases
according to their vaccination status is shown in Fig. 2 and the
Supporting information (Table S2). In the group fully vaccinated
with the monovalent vaccine the most prevalent genotype was
G2P[4] (68%). In the unvaccinated group, G1P[8] and G2P[4]
genotypes were almost equally often found (33% and 32%,
respectively). There was a significant overall association
(p <0.001) between rotavirus vaccination status and genotype.
In particular, when individual genotypes were compared with
each other, significant differences were found between the
heterotypic DS-1-like G2P[4] strains and the homotypic
Wa-like G1P[8] strains (p <0.001), and G2P[4] strains and
partially homotypic G4P[8] strains (p 0.004; Fig. 2).
To further investigate this finding, we compared the
prevalence of G1P[8] and G2P[4] rotaviruses in vaccinated
and unvaccinated cases in other clinical trials with the
monovalent vaccine [10–12,14,29–32], using the same meth-
ods as in this study (Table 2). Note that the case definition of
the rotavirus-positive study subjects for six out of nine trials
differed slightly from the present study’s case definition.
The distribution of G1P[8] and G2P[4] strains with respect
to the vaccination status differed significantly in most studies
containing a relatively high number of G1 and G2 cases (>50),
such as the studies of Linhares et al. [11] (p 0.044), and
Ruiz-Palacios et al. [14] (p 0.005). Both studies used the same
case definition as this study. In the study of Vesikari et al. [12]
in European infants, a statistically significant difference was also
observed in a 2-year study period (p 0.003; Table 2). The
study of Li et al. [31] conducted in China was the only study,
containing a large number of cases infected with either a G1 or
G2 rotavirus, were no statistical difference was found between
the vaccination status and the distribution of G1 and G2
rotavirus strains (p 0.502). Five studies had a relatively limited
number of G1 and G2 cases (<50), including a study conducted
in Singapore by Phua et al. [10] (22 cases), a study by
Kawamura et al. [30] in Japanese children (20 cases), a study
conducted in Malawi and South Africa by Steele et al. [32] (14
and 36 cases, respectively) and a study conducted by Tregnaghi
TABLE 1. Effectiveness against hospitalized rotavirus gastroenteritis of a full series vaccination with the monovalent vaccine by
genotype
Genotype
Number of cases Number of controls
Vaccine effectiveness (95% CI)Fully vaccinated* Unvaccinated Fully vaccinateda Unvaccinated
G1P[8] 11 30 48 4 95 (78–99)
G2P[4] 46 34 93 10 85 (64–94)
G3P[8] 4 8 11 2 87 (5 to 98)
G4P[8] 6 10 15 2 90 (19–99)
All genotypes 70 90 179 19 90 (81–95)
aFully vaccinated means two doses of the monovalent vaccine.
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FIG. 2. Statistical analyses of vaccination status per rotavirus geno-
type for 248 hospitalized rotavirus gastroenteritis cases. Percentages
and numbers of the most common human rotavirus genotypes found in
rotavirus gastroenteritis patients fully vaccinated with the monovalent
vaccine, unvaccinated patients and patients with other vaccination
status (partially vaccinated, vaccinated with the pentavalent vaccine,
unknown vaccination status) are shown together with their 95% CI.
Pairwise comparisons (post-hoc analyses) are indicated by brackets
above the bars.
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et al. [29] in Latin American children (four cases). In all five
studies no statistical difference could be detected or deter-
mined.
Hospitalized rotavirus gastroenteritis cases and co-infecting
pathogens
Co-infecting pathogens per vaccination status. Sixty-one out of
248 (24.6%) rotavirus gastroenteritis cases were co-infected
with astrovirus, adenovirus and/or norovirus. Astrovirus,
adenovirus and norovirus co-infections were found in 26
(10.5%), 24 (9.7%) and 3 (1.2%) cases, respectively. In addition,
one (0.4%) case was found to be co-infected with both
astrovirus and norovirus, and another 7 (2.8%) cases with both
astrovirus and adenovirus. No association was found between
vaccination status and co-infecting pathogen (p 0.33) (Fig. 3
and Supporting information, Table S3).
Co-infecting pathogens per Vesikari severity scale. In all, 139 (56%)
patients hospitalized with rotavirus gastroenteritis were clas-
sified as severe according to the Vesikari scale (i.e. a score ≥11
points). To investigate whether co-infection with another viral
cause of gastroenteritis (astrovirus, adenovirus or norovirus)
would result in a more severe clinical manifestation, we
compared the viral co-infection status with the Vesikari score.
No overall significant difference (p 0.64) was observed
between co-infected cases (astrovirus, adenovirus, norovirus,
TABLE 2. Statistical comparison of the proportion of G1P[8] and G2P[4] rotavirus strains in cases vaccinated with the
monovalent vaccine and unvaccinated cases, in the present study and nine clinical trials ordered according to their total number
of cases
Genotype-specific
rotavirus
gastroenteritis
Vaccine efficacy/
effectivenessa
(95% CI)
Monovalent vaccine
no. of cases (%)
Placebo/Unvaccinated
no. of cases (%)
Total number
of cases (%) p-value b
Matthijnssens et al. (present study)c
Total number of cases: 95 118 213
G1 94.67 (77.54–98.74) 13 (13.7) 39 (33.1) 52 (24.4) <0.001
G2 85.00 (63.69–93.80) 65 (68.4) 38 (32.2) 103 (48.4)
Vesikari et al. 2007 [12]d
Combined follow-up period
Total number of cases: 79 205 284
G1 89.8 (82.9–94.2) 18 (22.8) 89 (43.4) 107 (37.7) 0.003
G2 58.3 (10.1–81.0) 14 (17.7) 17 (8.3) 31 (10.9)
Li et al. 2013 [31]d
Total number of cases: 70 167 237
G1 52.2 (19.0–72.6) 20 (28.6) 38 (22.8) 58 (24.5) 0.502
G2 58.9 (40.5–72.0) 42 (60.0) 102 (61.1) 144 (60.8)
Linhares et al. 2008 [11]e
Total number of cases: 30 154 184
G1 82.1 (64.6–91.9) 8 (26.7) 53 (34.4) 61 (33.2) 0.044
G2 38.6 (<0–84.2) 5 (16.7) 8 (5.2) 13 (7.1)
Ruiz-Palacios et al. 2006 [14]e
Total number of cases: 11 72 83
G1 91.8 (74.1–98.4) 2 (18.2) 34 (47.2) 36 (43.4) 0.005
G2 41.0 (79.2–82.4) 6 (54.5) 9 (12.5) 15 (18.1)
Steele et al. 2012 [32]d
Malawi
Total number of cases: 41 38 79
G1 43.7 (133.1–85.7) 6 (14.6) 5 (13.2) 11 (13.9) 1.000
G2 6.2 (5433.1–95.1) 2 (4.9) 1 (2.6) 3 (3.8)
Steele et al. 2012 [32]d
South Africa
Total number of cases: 15 37 52
G1 69.8 (32.5–87.1) 11 (73.3) 18 (48.6) 29 (55.8) 0.3839
G2 91.8 (32.2–99.8) 1 (6.7) 6 (16.2) 7 (13.5)
Phua et al. 2009[10]f
Total number of cases: 2 48 50
G1 100 (80.8–100) 0 (0.0) 20 (41.7) 20 (40.0) Could not be
determinedG2 100 (431.7–100) 0 (0.0) 2 (4.17) 2 (4.0)
Kawamura et al. 2011 [30]g
Total number of cases: 14 34 48
G1 84.6 (50.0–96.3) 4 (28.6) 13 (38.2) 17 (35.4) 1.000
G2 74.9 (382.2–99.6) 1 (7.1) 2 (5.9) 3 (6.3)
Tregnaghi et al. 2011 [29]d
Total number of cases: 7 19 26
G1 100 (1844.0–100) 0 (0.0) 1 (5.3) 1 (3.85) 1.000
G2 75.1 (378.7–99.6) 1 (14.3) 2 (10.5) 3 (11.5)
aVaccine efficacy data as determined in the original study, including cases with double infections.
bTwo-sided p-values (post-hoc analyses) determined by Fisher’s exact test between G1 and G2. p-values lower than 0.05 are shown in bold.
cClinical case definition with at least two episodes of vomiting and/or three episodes of diarrhoea within a 24-h period not due to an underlying medical condition and requiring at
least one overnight stay with oral or intravenous rehydration therapy (equivalent to WHO plan B or C). Cases with double infections were omitted.
dClinical case definition with at least three episodes of three looser than normal stools within a 24-h period with or without vomiting.
eClinical case definition with at least an episode of diarrhoea (passage of three or more looser than normal or watery stools within a 24-h period) with or without vomiting that
required overnight hospitalization or rehydration therapy (equivalent to WHO plan B or C) in a medical facility such as a hospital, clinic or supervised rural health care centre.
Cases with double infections were omitted.
fClinical case definition as in e and with additional criterion of a score ≥11 points on the 20-point Vesikari-scale.
gClinical case as in d, but symptoms led to a medical intervention.
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astrovirus/norovirus, or astrovirus/adenovirus) and cases
without a co-infection regarding the Vesikari score (mild-
moderate vs. severe vs. missing) (Fig. 4 and Supporting
information, Table S4).
Co-infecting pathogens per rotavirus genotype. Out of the 61
hospitalized rotavirus gastroenteritis cases co-infected, 43%
were G2P[4], 28% G1P[8], 15% G4P[8], 8% G9P[8] and 7%
G3P[8] (see Supporting information, Table S5). No significant
difference (p 0.78) was observed in the overall distribution of
co-infecting pathogens for the different rotavirus genotypes.
Discussion
The study aimed to investigate the rotavirus vaccine effective-
ness against different circulating rotavirus genotypes, and to
assess the possible effect of co-infections on disease severity
and genotype distribution. In a post-hoc analysis we also
investigated the genotype distribution per vaccination status.
Natural rotavirus infection or vaccination with a live oral
vaccine normally results in immunological responses providing
both homotypic and heterotypic protection. This is reflected
in a higher vaccine effectiveness of a full series (two doses) of
the monovalent vaccine against circulating homotypic G1P[8]
rotavirus strains, compared with the circulating heterotypic
G2P[4] rotavirus strains—95% (95% CI 77.5–98.7) versus 85%
(95% CI 63.7–93.8), respectively (Table 1).
The analysis showed a statistically significant higher pro-
portion of G2P[4] strains in vaccinated cases than in unvac-
cinated cases. This was also found in the majority of clinical
studies for the monovalent vaccine containing >50 G1 and G2
cases (Table 2). Besides the study of Li et al. [31] and Steele
et al. [32], conducted in South Africa, all studies showed a
lower point estimate of vaccine effectiveness against rotavirus
gastroenteritis caused by the heterotypic G2P[4] strains than
against rotavirus gastroenteritis caused by fully homotypic G1P
[8], which subsequently translates to a higher prevalence of
G2P[4] strains in vaccinated cases compared with unvaccinated
cases. In line with this observation, Adlhoch et al. [33] showed
that during rotavirus surveillance G2P[4] genotypes were
more frequently found in breakthrough cases vaccinated with
the monovalent vaccine.
From a biological point of view, the finding that the use of
vaccines possessing a single or limited number of viral or
bacterial strains/types may influence the distribution of
co-circulating pathogens in a population is not unexpected,
and it is in concordance with the observations of changes in
strain/type prevalence after vaccine introduction for other
microorganisms, such as human immunodeficiency virus 1 [34]
and Streptococcus pneumoniae [35] among others.
Strong seasonal and geographical rotavirus genotype fluc-
tuations have also been observed in the absence of vaccines
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FIG. 3. Statistical analyses of co-infection status by vaccination status
for 248 hospitalized rotavirus gastroenteritis cases. Percentages and
numbers of patients without co-infection or co-infected with astro-
virus, norovirus and/or adenovirus found in rotavirus gastroenteritis
cases fully vaccinated with the monovalent vaccine, unvaccinated cases
and cases with other vaccination status (partially vaccinated, vaccinated
with pentavalent vaccine, unknown vaccination status) are shown
together with their 95% CI.
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FIG. 4. Statistical analyses of co-infection status versus gastroenter-
itis disease severity measured by the Vesikari score for 248 hospital-
ized rotavirus gastroenteritis cases. Percentages and numbers of
patients without co-infection or co-infected with astrovirus, norovirus,
adenovirus, astrovirus/norovirus or astrovirus/adenovirus found with
mild/moderate gastroenteritis, severe gastroenteritis or missing
Vesikari severity score are shown together with their 95% CI.
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[6,19]. Currently, the factors causing these fluctuations are
largely unknown, although immunity present in a population
due to previous virus exposure, and unknown stochastic
variables are likely to play an important role. In addition,
differences in genotype-specific vaccine effectiveness and the
resulting influence on the distribution of co-circulating rota-
virus strains, could help to explain the increase in the
proportion of G2P[4] strains among the remaining severe
rotavirus infections after the introduction of the monovalent
vaccine into national immunization schedules, as has been
noted in Brazil [36] and to a lesser extent in Australia [37].
Also in Belgium, the strongly decreasing number of rotavirus
hospitalizations in three consecutive rotavirus seasons (2006–
2009) after vaccine introduction coincided with a higher
proportion of G2P[4] rotavirus strains [19]. Unpublished data
for the 2009–2013 rotavirus seasons in Belgium indicate that
the rotavirus gastroenteritis incidence was between 4.9% and
7.2% of all hospitalized gastroenteritis cases tested for
rotavirus and that the proportion of G2P[4] ranged from
16.0% to 64.8% of the remaining rotavirus cases. The latest
published and unpublished data from EuroRotaNet do not
show a similar prolonged increased proportion of G2P[4]
strains in neighbouring countries of Belgium, or any other
European countries [6]. This coincides with the fact that
Belgium is the only country in Europe where the monovalent
vaccine was used for multiple seasons with consistently high
vaccination coverage.
To our knowledge, this is the first rotavirus vaccine
effectiveness study that also takes into account co-infection
with other viral pathogens. To our surprise, no statistically
significant association was found between viral co-infections
with adenovirus, norovirus or astrovirus and disease severity,
indicating that multiple viral infections did not result in a more
severe clinical disease manifestation. Also, no association was
found between co-infection pathogens and vaccination status,
suggesting that vaccine breakthrough cases were most likely not
attributable to gastroenteritis caused by co-infecting pathogens.
Furthermore no association between co-infecting pathogens
and rotavirus genotypes was found, indicating that the higher
proportion of G2P[4] strains in the vaccinated population
cannot be attributed to an increase in co-infecting pathogens.
However, we only screened for the most common viral
causative agents of gastroenteritis, while other, mainly bacterial,
causative agents could also affect the outcomes of this study.
This is the first European study to estimate genotype-spe-
cific effectiveness of a rotavirus vaccine in a post-marketing
setting using a robust case–control design and the first to
investigate the potential impact of common viral intestinal
co-infections on rotavirus vaccine effectiveness [27]. However,
this study was not specifically designed to evaluate if rotavirus
vaccination may influence the proportion of G2P[4] strains in
the rotavirus population. Therefore there is a need for
continued longer-term monitoring of the rotavirus genotype
distribution in environments with universal rotavirus vaccina-
tion programmes to elucidate what the relative importance of
vaccination is compared with other factors shaping the yearly
changing genotype distribution.
Rotavirus surveillance and detailed strain analyses will
remain crucial in the future, because rotavirus strains for
which vaccines show a lower vaccine effectiveness might
prevail and because new rotavirus variants can be disseminated
across the globe in a short time span [2]. Nevertheless, the
vaccine effectiveness against hospitalized rotavirus gastroen-
teritis cases by individual homotypic and heterotypic rotavirus
genotypes in Belgium was shown to be high (95% against G1P
[8], 85% against G2P[4], 87% against G3P[8] and 90% against
G4P[8]), implying robust protection of the monovalent vaccine
against hospitalized rotavirus gastroenteritis caused by the
major currently circulating human rotavirus genotypes.
Acknowledgements
This work was performed at the request of the European
Medicines Agency (EMA). This study was coordinated and
conducted by the University of Antwerp, which obtained
funding from GlaxoSmithKline Biologicals SA to perform the
study. The funders had a role in study design, data collection
and analysis. JM was supported by an FWO (‘Fonds voor
Wetenschappelijk Onderzoek’) post-doctoral fellowship. MZ
was supported by the Institute for the Promotion of Innova-
tion through Science and Technology in Flanders (IWT
Vlaanderen). This study was co-financed by the University of
Antwerp’s concerted research action project nr 23405
(BOF-GOA) to PVD. We recognize the invaluable contribu-
tion of all staff involved in the conduct of this study at all the
participating hospitals. Parts of the study results have been
presented previously at the 29th Annual meeting of the
European Society for Paediatric Infectious diseases.
Author Contributions
NM, PVD, MS-G, KVH, JM and MVR designed the study.
Clinical staff from GSK contributed on the study set up in all
centres. MA, HC, JDK, A-SM, MR, LV, MV, AV and the RotaBel
study group were responsible for enrolment of participants
and data acquisition. SDC, EH, MZ and JM performed the
laboratory analysis. TB was responsible for data acquisition,
data management, training and coordination of study staff. MZ,
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI
CMI Matthijnssens et al. Genotype-specific vaccine effectiveness 7
JV and Statisticians from GSK worked on aspects of the
statistical analyses. JM, MZ, PVD, KVH and MVR wrote the
manuscript. Publication coordination and editorial manage-
ment were provided by JM, MZ and GSK. All authors had
access to the data used in this paper, contributed to the
writing of the manuscript, and have seen and approved the final
version.
Transparency Declaration
The Laboratory of Clinical and Epidemiological Virology (MVR,
JM, SDC, MZ, EH, JV) received grants from GlaxoSmithKline
Biologicals SA, Merck Research Laboratory and Zoetis for
rotavirus research. MZ and EH received money for travel and
accommodation from GSK for ESPID. ASM received institu-
tional grants from GlaxoSmithKline Biologicals SA. NM and JYP
are employees of GlaxoSmithKline group of companies. MR
received institutional grants from GlaxoSmithKline group of
companies for board membership and lectures and speakers
bureau. MSG was an employee of GlaxoSmithKline group of
companies between 2005 and 2010 and held stock options.
PVD acts as chief and principal investigator for vaccine trials
conducted on behalf of the University of Antwerp, for which
the University obtains research grants from several vaccine
companies, and received payment for lectures which are
transferred to an educational fund of the University. MVR
received institutional grants from GlaxoSmithKline Biologicals
SA, received institutional grants for consultancy with Glaxo-
SmithKline Biologicals SA, SP-MSD, Johnson & Johnson, and
talks at meetings of general practitioners where the meeting
was sponsored by GlaxoSmithKline Biologicals SA, Merck, or
other companies.
Supporting Information
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Genotype distribution of hospitalized rotavirus
gastroenteritis cases per rotavirus season.
Table S1. Primers used in (RT-) PCR and sequencing
protocols.
Table S2. Distribution of status of vaccination by rotavirus
genotypes for 248 hospitalized rotavirus gastroenteritis cases.
Table S3. Percentage of rotavirus gastroenteritis hospital-
izations attributable to co-infected patients by vaccination
status for 248 hospitalized rotavirus gastroenteritis cases.
Table S4. Percentage of rotavirus gastroenteritis hospital-
izations attributable to co-infected patients by Vesikari score
for 248 hospitalized rotavirus gastroenteritis cases.
Table S5. Distribution of rotavirus genotypes by co-infec-
tion status for 248 hospitalized rotavirus gastroenteritis cases.
References
1. Estes M, Kapikian A. Rotaviruses. In: Knipe DM, Howley PM, Griffin DE
et al., eds. Field’s Virology, 5th edn. Philadelphia: Kluwer Health/
Lippincott, Williams and Wilkins, 2007; 1917–1974.
2. Matthijnssens J, Heylen E, Zeller M, Rahman M, Lemey P, Van Ranst M.
Phylodynamic analyses of rotavirus genotypes g9 and g12 underscore
their potential for swift global spread. Mol Biol Evol 2010; 27: 2431–
2436.
3. Matthijnssens J, Bilcke J, Ciarlet M et al. Rotavirus disease and
vaccination: impact on genotype diversity. Future Microbiol 2009; 4:
1303–1316.
4. Matthijnssens J, Ciarlet M, Heiman E et al. Full genome-based
classification of rotaviruses reveals a common origin between human
wa-like and porcine rotavirus strains and human ds-1-like and bovine
rotavirus strains. J Virol 2008; 82: 3204–3219.
5. Nakagomi O, Nakagomi T, Akatani K, Ikegami N. Identification of
rotavirus genogroups by RNA-RNA hybridization. Mol Cell Probes 1989;
3: 251–261.
6. Iturriza-Gomara M, Dallman T, Banyai K et al. Rotavirus genotypes
co-circulating in Europe between 2006 and 2009 as determined by
Eurorotanet, a pan-European collaborative strain surveillance network.
Epidemiol Infect 2010; 139: 895–909.
7. Matthijnssens J, Nakagomi O, Kirkwood CD, Ciarlet M, Dessel-
berger U, Van Ranst M. Group A rotavirus universal mass
vaccination: how and to what extent will selective pressure
influence prevalence of rotavirus genotypes? Expert Rev Vaccines
2012; 11: 1347–1354.
8. Ward RL, Bernstein DI. Rotarix: a rotavirus vaccine for the world. Clin
Infect Dis 2009; 48: 222–228.
9. Matthijnssens J, Joelsson DB, Warakomski DJ et al. Molecular and
biological characterization of the 5 human-bovine rotavirus
(wc3)-based reassortant strains of the pentavalent rotavirus vaccine,
Rotateq. Virology 2010; 403: 111–127.
10. Phua KB, Lim FS, Lau YL et al. Safety and efficacy of human
rotavirus vaccine during the first 2 years of life in Asian infants:
randomised, double-blind, controlled study. Vaccine 2009; 27: 5936–
5941.
11. Linhares AC, Velazquez FR, Perez-Schael I et al. Efficacy and safety of
an oral live attenuated human rotavirus vaccine against rotavirus
gastroenteritis during the first 2 years of life in Latin American infants:
a randomised, double-blind, placebo-controlled phase III study. Lancet
2008; 371: 1181–1189.
12. Vesikari T, Karvonen A, Prymula R et al. Efficacy of human rotavirus
vaccine against rotavirus gastroenteritis during the first 2 years of life
in European infants: randomised, double-blind controlled study. Lancet
2007; 370: 1757–1763.
13. Vesikari T, Matson DO, Dennehy P et al. Safety and efficacy of a
pentavalent human-bovine (wc3) reassortant rotavirus vaccine. N Engl J
Med 2006; 354: 23–33.
14. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR et al. Safety and efficacy
of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl
J Med 2006; 354: 11–22.
15. Armah GE, Sow SO, Breiman RF et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in developing
countries in sub-Saharan Africa: a randomised, double-blind,
placebo-controlled trial. Lancet 2010; 376: 606–614.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI
8 Clinical Microbiology and Infection CMI
16. Zaman K, Dang DA, Victor JC et al. Efficacy of pentavalent rotavirus
vaccine against severe rotavirus gastroenteritis in infants in developing
countries in Asia: a randomised, double-blind, placebo-controlled trial.
Lancet 2010; 376: 615–623.
17. Strategic Advisory Group of Experts SAGE. Meeting of the immuni-
zation strategic advisory group of experts, April 2009—conclusions
and recommendations. Wkly Epidemiol Rec 2009; 84: 220–236.
18. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, Van Damme
P. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J
2011; 30: S21–S24.
19. Zeller M, Rahman M, Heylen E et al. Rotavirus incidence and genotype
distribution before and after national rotavirus vaccine introduction in
Belgium. Vaccine 2010; 28: 7507–7513.
20. Studie van de vaccinatiegraag bij jonge kinderen en adolescenten in
vlaanderen in 2012 [in dutch], 2013. Available from: http://www.
zorg-en-gezondheid.be/vaccinatiegraad/.
21. Macartney KK, Porwal M, Dalton D et al. Decline in rotavirus
hospitalisations following introduction of Australia’s national rotavirus
immunisation programme. J Paediatr Child Health 2011; 47: 266–270.
22. Paulke-Korinek M, Kundi M, Rendi-Wagner P et al. Herd immunity
after two years of the universal mass vaccination program against
rotavirus gastroenteritis in Austria. Vaccine 2011; 29: 2791–2796.
23. Lanzieri TM, Linhares AC, Costa I et al. Impact of rotavirus vaccination
on childhood deaths from diarrhea in Brazil. Int J Infect Dis 2011; 15:
e206–e210.
24. Quintanar-Solares M, Yen C, Richardson V, Esparza-Aguilar M,
Parashar UD, Patel MM. Impact of rotavirus vaccination on diar-
rhea-related hospitalizations among children < 5 years of age in
Mexico. Pediatr Infect Dis J 2011; 30: S11–S15.
25. Becker-Dreps S, Paniagua M, Dominik R et al. Changes in childhood
diarrhea incidence in Nicaragua following 3 years of universal infant
rotavirus immunization. Pediatr Infect Dis J 2011; 30: 243–247.
26. Tate JE, Cortese MM, Payne DC et al. Uptake, impact, and effective-
ness of rotavirus vaccination in the United States: review of the first
3 years of postlicensure data. Pediatr Infect Dis J 2011; 30: S56–S60.
27. Braeckman T, Van Herck K, Meyer N et al. Effectiveness of rotavirus
vaccination in prevention of hospital admissions for rotavirus gastro-
enteritis among young children in Belgium: case–control study. BMJ
2012; 345: e4752.
28. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of
numerical scores for clinical severity of diarrhoeal episodes. Scand J
Infect Dis 1990; 22: 259–267.
29. Tregnaghi MW, Abate HJ, Valencia A et al. Human rotavirus vaccine is
highly efficacious when coadministered with routine expanded pro-
gram of immunization vaccines including oral poliovirus vaccine in Latin
America. Pediatr Infect Dis J 2011; 30: e103–e108.
30. Kawamura N, Tokoeda Y, Oshima M et al. Efficacy, safety and
immunogenicity of rix4414 in Japanese infants during the first two
years of life. Vaccine 2011; 29: 6335–6341.
31. Li RC, Huang T, Li Y et al. Human rotavirus vaccine (rix4414) efficacy
in the first two years of life: a randomized, placebo-controlled trial in
China. Hum Vaccin Immunother 2013; 10: 11–18.
32. Steele AD, Neuzil KM, Cunliffe NA et al. Human rotavirus vaccine
Rotarix provides protection against diverse circulating rotavirus strains
in African infants: a randomized controlled trial. BMC Infect Dis 2012;
12: 213.
33. Adlhoch C, Hoehne M, Littmann M et al. Rotavirus vaccine effective-
ness and case–control study on risk factors for breakthrough infections
in Germany, 2010–2011. Pediatr Infect Dis J 2013; 32: e82–e89.
34. Rolland M, Tovanabutra S, deCamp AC et al. Genetic impact of
vaccination on breakthrough HIV-1 sequences from the step trial. Nat
Med 2011; 17: 366–371.
35. Davies TA, Yee YC, Bush K, Sahm D, Evangelista A, Goldschmidt R.
Effects of the 7-valent pneumococcal conjugate vaccine on u.S.
Levofloxacin-resistant Streptococcus pneumoniae. Microb Drug Resist
2008; 14: 187–196.
36. Nakagomi T, Cuevas LE, Gurgel RG et al. Apparent extinction of
non-g2 rotavirus strains from circulation in Recife, Brazil, after the
introduction of rotavirus vaccine. Arch Virol 2008; 153: 591–593.
37. Kirkwood CD, Boniface K, Barnes GL, Bishop RF. Distribution of
rotavirus genotypes after introduction of rotavirus vaccines, Rotarix
and Rotateq, into the national immunization program of Australia.
Pediatr Infect Dis J 2011; 30: S48–S53.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI
CMI Matthijnssens et al. Genotype-specific vaccine effectiveness 9
